Craig Martin | Founder, CEO
Orphan Therapeutics Accelerator

Craig is a highly experienced executive, founder, advisor, and board director with a deep background in biotechnology and life sciences. He’s dedicated his career to advancing new technologies and treatments to improve health, including gene editing, mRNA, microbiome-based treatments, genomic sequencing, molecular diagnostics, wearables, and digital health. His focus in emerging innovation and desire to make an impact have led to a longstanding commitment to supporting advancement of novel technologies and treatment approaches for rare and genetic diseases. He has founded, run and advised for-profit and non-profit organizations advancing and expanding access to treatments for rare, genetic conditions. In June 2024, Craig founded the Orphan Therapeutics Accelerator (OTXL), a unique biotech leveraging tax and other incentives to acquire, fund, complete development and commercialize promising clinical-stage treatments for ultra-rare diseases. In August 2025, OTXL established a commercial-stage subsidiary, Orphan Therapies, now partnering with Fondazione Telethon to commercialize WASKYRA®, a gene therapy for an ultra-rare immunological disorder. In January 2026, OTXL formed a joint venture with the American Society for Gene & Cell Therapy (ASGCT) to establish CGTxchange, an AI-enabled marketplace and financing platform to support and scale funding and advancement of cell and gene therapies that demonstrated effectiveness and safety in trials but were shelved due to shifting sponsor priorities or other considerations. Craig is also President of RITHM Health, Inc., a strategy consultancy he founded in 2018. He has served on the board and more recently as CEO of Global Genes, a leading rare disease organization. Prior to this, he was a Global Principal for Biotech and Health Technology at Ogilvy Consulting and CEO of Ogilvy’s Feinstein Kean Healthcare. He’s held leadership positions with companies based in Cambridge, MA, Washington, D.C., New York, and Brussels, Belgium. He currently serves on the boards of Orphan Therapeutics Accelerator and the Fibrolamellar Cancer Foundation and is a frequent speaker and commentator on health innovation, rare disease and treatment access.